Longitudinal Metabolomics in Amyotrophic Lateral Sclerosis Implicates Impaired Lipid Metabolism
Open Access
- 20 February 2025
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 98 (1) , 19-34
Abstract
Objective: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by altered metabolome and energy homeostasis, manifesting with body mass index changes and hypermetabolism—both prognostic of disease progression and survival. The cross‐sectional ALS metabolome has been characterized, but longitudinal correlations to functional decline are lacking.Methods: We longitudinally evaluated metabolomes from ALS plasma and terminal postmortem spinal cord and brain motor cortex tissue. We constructed 3 plasma models. A linear mixed effects model correlated all metabolite levels across all timepoints to their corresponding functional scores. An interaction model predicted a longitudinal change in function from baseline metabolites, whereas a progression model identified metabolites linked to a 20% or 50% drop in function. In postmortem samples, differential metabolites in onset versus second spinal cord segments served as a surrogate of disease progression. Mendelian randomization assessed potential causality from metabolites.Results: In plasma, all models primarily selected lipid metabolites and sub‐pathways, in addition to amino acids, xenobiotics, and various less frequently selected pathways. Among lipids, fatty acids and sphingomyelins were predominant, along with plasmalogens, phosphatidylcholines, and lysophospholipids. Sex interaction findings were nominal. In the spinal cord, sphingomyelin and long‐chain saturated and monounsaturated fatty acids were more abundant in the onset segment tissue, whereas phosphatidylcholines and phosphatidylethanolamines were less abundant. Mendelian randomization suggested that impaired carnitine and short chain acylcarnitine metabolism may be genetically determined in ALS, along with various antioxidant derivatives.Interpretation: Our findings suggest metabolomic changes primarily involving different lipid classes and carnitine metabolism may underscore ALS severity and progression. ANN NEUROL 2025;98:19–34Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS127188)
- Michigan Institute for Clinical and Health Research (UL1TR000433)
- Centers for Disease Control and Prevention (R01TS000289)
- National Institute of Environmental Health Sciences (K23ES027221, R01ES030049)
This publication has 59 references indexed in Scilit:
- Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profilesMuscle & Nerve, 2022
- Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort studyJournal of Neurology, 2019
- The role of nonbilayer phospholipids in mitochondrial structure and functionFEBS Letters, 2017
- Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry SwabiaEuropean Journal of Epidemiology, 2017
- Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline MetabolismMolecular Neurobiology, 2016
- Association of Environmental Toxins With Amyotrophic Lateral SclerosisJAMA Neurology, 2016
- Amino Acids as biomarkers in the SOD1G93A mouse model of ALSBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- The Kennedy pathway—De novo synthesis of phosphatidylethanolamine and phosphatidylcholineIUBMB Life, 2010
- Hypermetabolism in ALS patients: an early and persistent phenomenonJournal of Neurology, 2009
- El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosisJournal of the Neurological Sciences, 1994